Cushing Syndrome Clinical Trial
Official title:
Long-Term Post-Operative Follow-Up of Cushing Syndrome
Although most patients with hypercortisolism can be diagnosed and treated the long-term
effects of hypercortisolism and its treatment are unknown. This study will attempt to answer
the following questions:
1. What is the rate of perioperative complications? Patients with Cushing syndrome often
undergo transsphenoidal surgery of the pituitary gland as treatment for the disease.
During this surgical procedure the pituitary gland is reached by passing through the
sphenoid bone. The risk for patients to develop hypopituitarism in the immediate
postoperative period is unknown. Patients with Cushing syndrome have abnormal levels of
hormones circulating in the blood and affects of the surgery are often not apparent
until long after the procedure.
2. What is the recurrence rate? The recurrence rate of the disease has been estimated
between 5 - 10%. However, these figures have not been confirmed. If the actual rate of
recurrence is higher than estimated many patients may elect to undergo radiation
therapy which has a lower rate of recurrence.
3. Do any factors in the immediate postoperative period predict who will experience a
recurrence of Cushing syndrome?
4. What are the long-term complications of hypercortisolism? Studies have shown that
patients with hypercortisolism have a four times greater risk of death than people of
the same age without hypercortisolism. Researchers tend to believe this figure is too
high. However, it is well established that hypercortisolism weakens bones (decreased
bone density), causes secondary hypogonadism, increases levels of fat in the blood
(hyperlipidemia), and decreases thyroid function (hypothyroidism). The potential for
these conditions to be reversed is not known.
These questions will be addressed by blood and urine sampling in the postoperative period,
and by outpatient follow-up and periodic questionnaires in the first 10 years after curative
surgery for Cushing syndrome performed at the NIH.
Status | Completed |
Enrollment | 500 |
Est. completion date | September 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Patients with Cushing syndrome documented at the NIH will be recruited into this protocol prior to surgery intended to cure Cushing syndrome selectively. Thus, patients undergoing transsphenoidal exploration for resection of an adenoma, or unilateral adrenalectomy for an adenoma, or resection of a tumor producing ACTH ectopically will be candidates for this study. We will also recruit as many of the 500 patients treated since 1983 as possible, so as to have a group of "late follow-up" patients. These individuals will participate primarily by questionnaire. Hematocrit about 30%. A CBC will be obtained prior to entering the study. Patients with hematocrit above 30% will be accepted into the study; iron replacement will be given to those patients with low TIBC. Ages 18 - 85. Children less than 18 are being studied under other protocols and the questionnaire has not been validated for younger individuals. For the questionnaire portion of the protocol there is an additional inclusion criterion: Patients must be able to read and write in English. EXCLUSION CRITERIA: There are no formal exclusion criteria, if the patient meets the inclusion criteria above. All ethnic groups and both genders will be recruited. However, patients may be withdrawn from the study by the PI if they are unable to meet study requirments, such as mailing questionnaires. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Child Health and Human Development (NICHD) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982 Sep 18;2(8299):646-9. — View Citation
Tarlov AR, Ware JE Jr, Greenfield S, Nelson EC, Perrin E, Zubkoff M. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA. 1989 Aug 18;262(7):925-30. — View Citation
Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997 Aug;6(6):531-54. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT05881005 -
NAC- NAFLD And Cushing
|
N/A | |
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Terminated |
NCT03379363 -
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
|
||
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Recruiting |
NCT05911620 -
Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism
|
N/A | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Recruiting |
NCT04045015 -
Liquorice and Salivary Cortisol
|
N/A | |
Recruiting |
NCT05804669 -
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
Recruiting |
NCT03343470 -
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
|
||
Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
Terminated |
NCT02001051 -
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
|
Phase 2 | |
Completed |
NCT03697109 -
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT03604198 -
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
|
Phase 2 | |
Completed |
NCT05347979 -
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01382420 -
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
|
N/A | |
Completed |
NCT00001849 -
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
|
Phase 2 | |
Recruiting |
NCT06229405 -
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
|
||
Recruiting |
NCT03211624 -
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
|